Imperial College Innovations Limited Licenses T Cell Receptor (TCR) Therapy Technology To GANYMED Pharmaceuticals AG
10/19/2005 5:09:21 PM
Transaction valuation potentially £1 million plus royalties on future product sales. Imperial College Innovations Ltd announced today an agreement to license exclusively patents covering the use of T Cell Receptor (TCR) Therapy Technologies and the production of TCRs, developed by Professor Hans Stauss in the Department of Immunology at Imperial College London, to GANYMED Pharmaceuticals AG.
comments powered by